A Multi-center, Phase III, Randomized, Observer Blind Study to Evaluate the Safety, Tolerability and Immunogenicity of a Trivalent Subunit Inactivated Flu Vaccine in Healthy Children and Adolescents 3 to 17 Years of Age

Trial Profile

A Multi-center, Phase III, Randomized, Observer Blind Study to Evaluate the Safety, Tolerability and Immunogenicity of a Trivalent Subunit Inactivated Flu Vaccine in Healthy Children and Adolescents 3 to 17 Years of Age

Completed
Phase of Trial: Phase III

Latest Information Update: 07 May 2014

At a glance

  • Drugs Influenza virus vaccine (Primary)
  • Indications Influenza virus infections
  • Focus Therapeutic Use
  • Sponsors Novartis; Novartis Vaccines
  • Most Recent Events

    • 15 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Mar 2011 Additional locations (Colombia, Mexico, Panama) identified as reported by ClinicalTrials.gov.
    • 30 Mar 2011 Planned end date changed from 1 Jul 2011 to 1 Sep 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top